These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 22966992)

  • 21. Non-alcoholic fatty liver disease.
    Tuyama AC; Chang CY
    J Diabetes; 2012 Sep; 4(3):266-80. PubMed ID: 22564417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
    Serfaty L; Lemoine M
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic assessment of non-alcoholic fatty liver disease.
    Bondini S; Kleiner DE; Goodman ZD; Gramlich T; Younossi ZM
    Clin Liver Dis; 2007 Feb; 11(1):17-23, vii. PubMed ID: 17544969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic steatohepatitis and metabolic syndrome.
    Machado M; Cortez-Pinto H
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.
    Coulon S; Francque S; Colle I; Verrijken A; Blomme B; Heindryckx F; De Munter S; Prawitt J; Caron S; Staels B; Van Vlierberghe H; Van Gaal L; Geerts A
    Cytokine; 2012 Aug; 59(2):442-9. PubMed ID: 22658783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis.
    Blomme B; Francque S; Trépo E; Libbrecht L; Vanderschaeghe D; Verrijken A; Pattyn P; Nieuwenhove YV; Putte DV; Geerts A; Colle I; Delanghe J; Moreno C; Gaal LV; Callewaert N; Vlierberghe HV
    Dig Liver Dis; 2012 Apr; 44(4):315-22. PubMed ID: 22119618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease].
    Tannapfel A; Denk H; Dienes HP; Langner C; Schirmacher P; Trauner M; Flott-Rahmel B
    Z Gastroenterol; 2010 Apr; 48(4):486-98. PubMed ID: 20352596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M; Stauch C; Shaw J; Harrison SA
    Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
    Cuadrado A; Orive A; García-Suárez C; Domínguez A; Fernández-Escalante JC; Crespo J; Pons-Romero F
    Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease.
    Chandok N; Minuk G; Wengiel M; Uhanova J
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):53-8. PubMed ID: 22457860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.
    Moore JB
    Proc Nutr Soc; 2010 May; 69(2):211-20. PubMed ID: 20158939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
    Sanyal AJ
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials.
    Yilmaz Y
    Curr Drug Targets; 2013 Oct; 14(11):1357-66. PubMed ID: 24020975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.